Brooke A. Rabe
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Brooke A. Rabe has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Melanie L. Bell
Department of Epidemiology and Biostatistics, Mel and Enid Zuckerman College of Public Health, University of Arizona, Tucson, USA
4 shared publications - Benjamin Aceves
School of Public Health, San Diego State University, San Diego, USA
1 shared publication - David G. Marrero
The University of Arizona Health Sciences, Tucson, AZ, United States
1 shared publication - David O. Garcia
University of Arizona
1 shared publication Dean Billheimer
BIO5 Institute, University of Arizona, Tucson, Ariz; Department of Biostatistics and Epidemiology, University of Arizona, Tucson, Ariz
1 shared publicationDebra A. Stern
Asthma and Airway Disease Research Center, University of Arizona Health Sciences, Tucson, Ariz
1 shared publication
Latest Publications
- 26 February 2025
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 156 (2) , 352-360
Respiratory and nonrespiratory symptoms before age 1 year predict school-age asthma
- 26 February 2025
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 156 (2) , 352-360
Respiratory and nonrespiratory symptoms before age 1 year predict school-age asthma
- Open Access
- 21 September 2022
- Published by JMIR Publications Inc. in JMIR Formative Research
- Vol. 6 (9) , e37637
mHealth-Supported Gender- and Culturally Sensitive Weight Loss Intervention for Hispanic Men With Overweight and Obesity: Single-Arm Pilot Study
Background: Hispanic men have disproportionate rates of overweight and obesity compared with other racial and ethnic subpopulations. However, few weight loss interventions have been developed specifically for this high-risk group. Furthermore, the use of mobile health (mHealth) technologies to support lifestyle behavior changes in weight loss interventions for Hispanic men is largely untested. Objective: This single-arm pilot study examined the feasibility and acceptability of integrating mHealth technology into a 12-week gender- and culturally sensitive weight loss intervention (GCSWLI) for Hispanic men with overweight and obesity. Methods: A total of 18 Hispanic men (mean age 38, SD 10.9 years; mean BMI 34.3, SD 5.5 kg/m²; 10/18, 56% Spanish monolingual) received a GCSWLI, including weekly in-person individual sessions, a daily calorie goal, and prescription of ≥225 minutes of moderate-intensity physical activity per week. mHealth technology support included tailored SMS text messaging, behavior self-monitoring support using Fitbit Charge 2, and weight tracking using a Fitbit Aria Wi-Fi Smart Scale. Changes in weight from baseline to 12 weeks were estimated using a paired 2-tailed t test. Descriptive analyses characterized the use of Fitbit and smart scales. Semistructured interviews were conducted immediately after intervention to assess the participants’ weight loss experiences and perspectives on mHealth technologies. Results: Of 18 participants, 16 (89%) completed the 12-week assessments; the overall attrition rate was 11.1%. The mean weight loss at week 12 was −4.7 kg (95% CI 7.1 to −2.4 kg; P<.001). Participants wore the Fitbit 71.58% (962/1344) of the intervention days and logged their body weight using the smart scale (410/1344, 30.51% of the intervention days). Participants identified barriers to the use of the technology, such as lack of technological literacy and unreliable internet access for the smart scale. Conclusions: Although clinically significant weight loss was achieved by integrating mHealth technology into the GCSWLI, adherence to the prescribed use of technology was modest. Addressing barriers to the use of such technologies identified in our work may help to refine an mHealth intervention approach for Hispanic men. Trial Registration: ClinicalTrials.gov NCT02783521; https://clinicaltrials.gov/ct2/show/NCT02783521
- 21 September 2022
- Published by JMIR Publications Inc. in JMIR Formative Research
- Vol. 6 (9) , e37637
Open AccessmHealth-Supported Gender- and Culturally Sensitive Weight Loss Intervention for Hispanic Men With Overweight and Obesity: Single-Arm Pilot Study
Background: Hispanic men have disproportionate rates of overweight and obesity compared with other racial and ethnic subpopulations. However, few weight loss interventions have been developed specifically for this high-risk group. Furthermore, the use of mobile health (mHealth) technologies to support lifestyle behavior changes in weight loss interventions for Hispanic men is largely untested. Objective: This single-arm pilot study examined the feasibility and acceptability of integrating mHealth technology into a 12-week gender- and culturally sensitive weight loss intervention (GCSWLI) for Hispanic men with overweight and obesity. Methods: A total of 18 Hispanic men (mean age 38, SD 10.9 years; mean BMI 34.3, SD 5.5 kg/m²; 10/18, 56% Spanish monolingual) received a GCSWLI, including weekly in-person individual sessions, a daily calorie goal, and prescription of ≥225 minutes of moderate-intensity physical activity per week. mHealth technology support included tailored SMS text messaging, behavior self-monitoring support using Fitbit Charge 2, and weight tracking using a Fitbit Aria Wi-Fi Smart Scale. Changes in weight from baseline to 12 weeks were estimated using a paired 2-tailed t test. Descriptive analyses characterized the use of Fitbit and smart scales. Semistructured interviews were conducted immediately after intervention to assess the participants’ weight loss experiences and perspectives on mHealth technologies. Results: Of 18 participants, 16 (89%) completed the 12-week assessments; the overall attrition rate was 11.1%. The mean weight loss at week 12 was −4.7 kg (95% CI 7.1 to −2.4 kg; P<.001). Participants wore the Fitbit 71.58% (962/1344) of the intervention days and logged their body weight using the smart scale (410/1344, 30.51% of the intervention days). Participants identified barriers to the use of the technology, such as lack of technological literacy and unreliable internet access for the smart scale. Conclusions: Although clinically significant weight loss was achieved by integrating mHealth technology into the GCSWLI, adherence to the prescribed use of technology was modest. Addressing barriers to the use of such technologies identified in our work may help to refine an mHealth intervention approach for Hispanic men. Trial Registration: ClinicalTrials.gov NCT02783521; https://clinicaltrials.gov/ct2/show/NCT02783521
- 22 November 2019
- Published by Taylor & Francis in Statistics in Biopharmaceutical Research
- Vol. 12 (2) , 176-186
A Conservative Approach for Analysis of Noninferiority Trials With Missing Data and Subject Noncompliance
Non-inferiority clinical trials aim to show an experimental treatment is therapeutically no worse than standard of care, particularly if the new treatment is preferred for reasons such as cost, convenience, safety, and so on. Non-inferiority trials are by nature less conservative than superiority studies: protocol violations may increase bias toward the alternative hypothesis of non-inferiority. Our objective was to compare multiple imputation, a linear mixed model, and other methods for analyzing a longitudinal trial with missing data in intention-to-treat and per-protocol populations. We simulated trials with missing data and non-compliance due to treatment inefficacy under varying trial conditions (e.g. trajectory of treatment effects, correlation between repeated measures, and missing data mechanism), assessing each approach by estimating bias, type I error and power. We found that multiple imputation using auxiliary data on non-compliance in the imputation model performed best. A hybrid intention-to-treat/per-protocol multiple imputation approach with a missing not at random imputation model produced low type I error, was unbiased and maintained reasonable power to detect non-inferiority. We conclude that the anti-conservatism of non-inferiority trial estimands conforming with the intention-to-treat principle may be offset by imputation models that include variables on intercurrent events.
- 22 November 2019
- Published by Taylor & Francis in Statistics in Biopharmaceutical Research
- Vol. 12 (2) , 176-186
A Conservative Approach for Analysis of Noninferiority Trials With Missing Data and Subject Noncompliance
Non-inferiority clinical trials aim to show an experimental treatment is therapeutically no worse than standard of care, particularly if the new treatment is preferred for reasons such as cost, convenience, safety, and so on. Non-inferiority trials are by nature less conservative than superiority studies: protocol violations may increase bias toward the alternative hypothesis of non-inferiority. Our objective was to compare multiple imputation, a linear mixed model, and other methods for analyzing a longitudinal trial with missing data in intention-to-treat and per-protocol populations. We simulated trials with missing data and non-compliance due to treatment inefficacy under varying trial conditions (e.g. trajectory of treatment effects, correlation between repeated measures, and missing data mechanism), assessing each approach by estimating bias, type I error and power. We found that multiple imputation using auxiliary data on non-compliance in the imputation model performed best. A hybrid intention-to-treat/per-protocol multiple imputation approach with a missing not at random imputation model produced low type I error, was unbiased and maintained reasonable power to detect non-inferiority. We conclude that the anti-conservatism of non-inferiority trial estimands conforming with the intention-to-treat principle may be offset by imputation models that include variables on intercurrent events.
- Open Access
- 1 April 2019
- Published by Taylor & Francis in Patient Related Outcome Measures
- Vol. ume 10, 129-140
Analytical approaches and estimands to take account of missing patient-reported data in longitudinal studies
Patient-reported outcomes, such as quality of life, functioning, and symptoms, are used widely in therapeutic and behavioral trials and are increasingly used in drug development to represent the patient voice. Missing patient reported data is common and can undermine the validity of results reporting by reducing power, biasing estimates, and ultimately reducing confidence in the results. In this paper, we review statistically principled approaches for handling missing patient-reported outcome data and introduce the idea of estimands in the context of behavioral trials. Specifically, we outline a plan that considers missing data at each stage of research: design, data collection, analysis, and reporting. The design stage includes processes to prevent missing data, define the estimand, and specify primary and sensitivity analyses. The analytic strategy considering missing data depends on the estimand. Reviewed approaches include maximum likelihood-based models, multiple imputation, generalized estimating equations, and responder analysis. We outline sensitivity analyses to assess the robustness of the primary analysis results when data are missing. We also describe ad-hoc methods, including approaches to avoid. Last, we demonstrate methods using data from a behavioral intervention, where the primary outcome was self-reported cognition.
- 1 April 2019
- Published by Taylor & Francis in Patient Related Outcome Measures
- Vol. ume 10, 129-140
Open AccessAnalytical approaches and estimands to take account of missing patient-reported data in longitudinal studies
Patient-reported outcomes, such as quality of life, functioning, and symptoms, are used widely in therapeutic and behavioral trials and are increasingly used in drug development to represent the patient voice. Missing patient reported data is common and can undermine the validity of results reporting by reducing power, biasing estimates, and ultimately reducing confidence in the results. In this paper, we review statistically principled approaches for handling missing patient-reported outcome data and introduce the idea of estimands in the context of behavioral trials. Specifically, we outline a plan that considers missing data at each stage of research: design, data collection, analysis, and reporting. The design stage includes processes to prevent missing data, define the estimand, and specify primary and sensitivity analyses. The analytic strategy considering missing data depends on the estimand. Reviewed approaches include maximum likelihood-based models, multiple imputation, generalized estimating equations, and responder analysis. We outline sensitivity analyses to assess the robustness of the primary analysis results when data are missing. We also describe ad-hoc methods, including approaches to avoid. Last, we demonstrate methods using data from a behavioral intervention, where the primary outcome was self-reported cognition.
- 25 May 2018
- Published by Wiley in Pharmaceutical Statistics
- Vol. 17 (5) , 477-488
Missing data handling in non‐inferiority and equivalence trials: A systematic review
Summary: Background: Non‐inferiority (NI) and equivalence clinical trials test whether a new treatment is therapeutically no worse than, or equivalent to, an existing standard of care. Missing data in clinical trials have been shown to reduce statistical power and potentially bias estimates of effect size; however, in NI and equivalence trials, they present additional issues. For instance, they may decrease sensitivity to differences between treatment groups and bias toward the alternative hypothesis of NI (or equivalence).Aims: Our primary aim was to review the extent of and methods for handling missing data (model‐based methods, single imputation, multiple imputation, complete case), the analysis sets used (Intention‐To‐Treat, Per‐Protocol, or both), and whether sensitivity analyses were used to explore departures from assumptions about the missing data.Methods: We conducted a systematic review of NI and equivalence trials published between May 2015 and April 2016 by searching the PubMed database. Articles were reviewed primarily by 2 reviewers, with 6 articles reviewed by both reviewers to establish consensus.Results: Of 109 selected articles, 93% reported some missing data in the primary outcome. Among those, 50% reported complete case analysis, and 28% reported single imputation approaches for handling missing data. Only 32% reported conducting analyses of both intention‐to‐treat and per‐protocol populations. Only 11% conducted any sensitivity analyses to test assumptions with respect to missing data.Conclusion: Missing data are common in NI and equivalence trials, and they are often handled by methods which may bias estimates and lead to incorrect conclusions.
- 25 May 2018
- Published by Wiley in Pharmaceutical Statistics
- Vol. 17 (5) , 477-488
Missing data handling in non‐inferiority and equivalence trials: A systematic review
Summary: Background: Non‐inferiority (NI) and equivalence clinical trials test whether a new treatment is therapeutically no worse than, or equivalent to, an existing standard of care. Missing data in clinical trials have been shown to reduce statistical power and potentially bias estimates of effect size; however, in NI and equivalence trials, they present additional issues. For instance, they may decrease sensitivity to differences between treatment groups and bias toward the alternative hypothesis of NI (or equivalence).Aims: Our primary aim was to review the extent of and methods for handling missing data (model‐based methods, single imputation, multiple imputation, complete case), the analysis sets used (Intention‐To‐Treat, Per‐Protocol, or both), and whether sensitivity analyses were used to explore departures from assumptions about the missing data.Methods: We conducted a systematic review of NI and equivalence trials published between May 2015 and April 2016 by searching the PubMed database. Articles were reviewed primarily by 2 reviewers, with 6 articles reviewed by both reviewers to establish consensus.Results: Of 109 selected articles, 93% reported some missing data in the primary outcome. Among those, 50% reported complete case analysis, and 28% reported single imputation approaches for handling missing data. Only 32% reported conducting analyses of both intention‐to‐treat and per‐protocol populations. Only 11% conducted any sensitivity analyses to test assumptions with respect to missing data.Conclusion: Missing data are common in NI and equivalence trials, and they are often handled by methods which may bias estimates and lead to incorrect conclusions.